$PTCT
PTC THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000107008124000023 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $196.8M
YoY Change 0.11%
Cost Of Revenue $10.85M
YoY Change 14.19%
Gross Profit $185.9M
YoY Change -0.62%
Gross Profit Margin 94.49%
Selling, General & Admin $73.46M
YoY Change -9.19%
% of Gross Profit 39.51%
Research & Development $161.4M
YoY Change -1.71%
% of Gross Profit 86.81%
Depreciation & Amortization $6.486M
YoY Change -89.55%
% of Gross Profit 3.49%
Operating Expenses $251.3M
YoY Change -20.16%
Operating Profit -$54.51M
YoY Change -53.87%
Interest Expense -$41.61M
YoY Change 47.76%
% of Operating Profit
Other Income/Expense, Net -$1.872M
YoY Change -90.76%
Pretax Income -$97.99M
YoY Change -41.18%
Income Tax $8.663M
% Of Pretax Income
Net Earnings -$106.7M
YoY Change -19.79%
Net Earnings / Revenue -54.2%
Basic Earnings Per Share -$1.39
Diluted Earnings Per Share -$1.39
COMMON SHARES
Basic Shares Outstanding 77.13M 76.92M
Diluted Shares Outstanding 76.93M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.013B
YoY Change 243.74%
Cash & Equivalents $526.0M
Short-Term Investments $487.4M
Other Short-Term Assets $32.55M
YoY Change -26.2%
Inventory $35.67M
Prepaid Expenses
Receivables $200.0M
Other Receivables $0.00
Total Short-Term Assets $1.282B
YoY Change 137.17%
LONG-TERM ASSETS
Property, Plant & Equipment $63.18M
YoY Change -25.7%
Goodwill $82.30M
YoY Change 0.0%
Intangibles $330.4M
YoY Change -21.96%
Long-Term Investments
YoY Change
Other Assets $25.34M
YoY Change -26.98%
Total Long-Term Assets $560.7M
YoY Change -22.08%
TOTAL ASSETS
Total Short-Term Assets $1.282B
Total Long-Term Assets $560.7M
Total Assets $1.842B
YoY Change 46.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.29M
YoY Change -30.6%
Accrued Expenses $98.44M
YoY Change -15.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $260.3M
YoY Change 139.86%
Total Short-Term Liabilities $610.7M
YoY Change 24.1%
LONG-TERM LIABILITIES
Long-Term Debt $285.1M
YoY Change -50.26%
Other Long-Term Liabilities $77.00K
YoY Change -45.39%
Total Long-Term Liabilities $285.2M
YoY Change -50.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $610.7M
Total Long-Term Liabilities $285.2M
Total Liabilities $2.897B
YoY Change 50.03%
SHAREHOLDERS EQUITY
Retained Earnings -$3.581B
YoY Change 14.49%
Common Stock $76.00K
YoY Change 1.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.054B
YoY Change
Total Liabilities & Shareholders Equity $1.842B
YoY Change 46.22%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$106.7M
YoY Change -19.79%
Depreciation, Depletion And Amortization $6.486M
YoY Change -89.55%
Cash From Operating Activities -$76.99M
YoY Change 430.25%
INVESTING ACTIVITIES
Capital Expenditures $522.0K
YoY Change -91.78%
Acquisitions
YoY Change
Other Investing Activities -$42.15M
YoY Change 81.38%
Cash From Investing Activities -$42.68M
YoY Change 44.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -17.63M
YoY Change -623.06%
NET CHANGE
Cash From Operating Activities -76.99M
Cash From Investing Activities -42.68M
Cash From Financing Activities -17.63M
Net Change In Cash -137.3M
YoY Change 236.92%
FREE CASH FLOW
Cash From Operating Activities -$76.99M
Capital Expenditures $522.0K
Free Cash Flow -$77.51M
YoY Change 271.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001070081
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76952124
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75708889
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35969
dei Entity Registrant Name
EntityRegistrantName
PTC Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3416587
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Warren Corporate Center Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Warren
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07059
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
222-7000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PTCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77125143
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
526001000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
594001000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
487356000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
282738000
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
199976000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
160822000
CY2024Q3 us-gaap Inventory Net
InventoryNet
35671000
CY2023Q4 us-gaap Inventory Net
InventoryNet
30577000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32546000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
150491000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1281550000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1218629000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63175000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87089000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
330368000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
379497000
CY2024Q3 us-gaap Goodwill
Goodwill
82341000
CY2023Q4 us-gaap Goodwill
Goodwill
82341000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59465000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91896000
CY2024Q3 ptct Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
25337000
CY2023Q4 ptct Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
36246000
CY2024Q3 us-gaap Assets
Assets
1842236000
CY2023Q4 us-gaap Assets
Assets
1895698000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
336346000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
391983000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
801000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14113000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13002000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2642000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3000000
CY2024Q3 ptct Liability Sale Of Future Royalties Current
LiabilitySaleOfFutureRoyaltiesCurrent
257611000
CY2023Q4 ptct Liability Sale Of Future Royalties Current
LiabilitySaleOfFutureRoyaltiesCurrent
194314000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
610712000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
603100000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
285106000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
284213000
CY2024Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22000000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
36300000
CY2024Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55909000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55905000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
82770000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
97627000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
15574000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17184000
CY2024Q3 ptct Liability Sale Of Future Royalties Noncurrent
LiabilitySaleOfFutureRoyaltiesNoncurrent
1824440000
CY2023Q4 ptct Liability Sale Of Future Royalties Noncurrent
LiabilitySaleOfFutureRoyaltiesNoncurrent
1619783000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
77000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
141000
CY2024Q3 us-gaap Liabilities
Liabilities
2896588000
CY2023Q4 us-gaap Liabilities
Liabilities
2714253000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76952124
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75708889
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
76000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
75000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2530902000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2466233000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4343000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1285000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3580987000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3283578000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1054352000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-818555000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1842236000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1895698000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
196786000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
196576000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
593608000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
630766000
CY2024Q3 ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
10848000
CY2023Q3 ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
9493000
ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
41115000
ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
36368000
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3036000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58649000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57431000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
145461000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
161412000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
164212000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
409710000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
545210000
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73456000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
80886000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
216228000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
256249000
CY2024Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-700000
CY2023Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-1500000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-5700000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
125000000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
217800000
CY2024Q3 ptct Gain Loss On Disposition And Impairment Of Tangible Assets
GainLossOnDispositionAndImpairmentOfTangibleAssets
-1844000
ptct Gain Loss On Disposition And Impairment Of Tangible Assets
GainLossOnDispositionAndImpairmentOfTangibleAssets
-3605000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
251296000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
314740000
us-gaap Operating Expenses
OperatingExpenses
733789000
us-gaap Operating Expenses
OperatingExpenses
1076088000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-54510000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-118164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-140181000
us-gaap Operating Income Loss
OperatingIncomeLoss
-445322000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-41609000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-28160000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-125933000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-84905000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1872000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20266000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2306000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8832000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-97991000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-166590000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-268420000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-539059000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8663000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-33620000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28989000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-68247000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-106654000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-132970000
us-gaap Net Income Loss
NetIncomeLoss
-297409000
us-gaap Net Income Loss
NetIncomeLoss
-470812000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76925523
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76925523
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75377997
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75377997
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76716340
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76716340
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74618611
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74618611
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.31
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-106654000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-132970000
us-gaap Net Income Loss
NetIncomeLoss
-297409000
us-gaap Net Income Loss
NetIncomeLoss
-470812000
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2760000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
19000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2204000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
470000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
9395000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
11021000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5262000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4343000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94499000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121930000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-300467000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-465999000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-980181000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
573000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19755000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-106654000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12155000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1054352000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-579268000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3446000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26942000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-132970000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11040000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-670810000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-818555000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5320000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1973000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57376000
us-gaap Net Income Loss
NetIncomeLoss
-297409000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3058000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1054352000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-347086000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23771000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3805000
ptct Stock Issued During Period Value Milestone Payable
StockIssuedDuringPeriodValueMilestonePayable
29570000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85128000
us-gaap Net Income Loss
NetIncomeLoss
-470812000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4813000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-670810000
us-gaap Net Income Loss
NetIncomeLoss
-297409000
us-gaap Net Income Loss
NetIncomeLoss
-470812000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68899000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
155885000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
6272000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8156000
ptct Noncash Royalty Revenue Sale Of Future Royalties
NoncashRoyaltyRevenueSaleOfFutureRoyalties
128877000
ptct Noncash Royalty Revenue Sale Of Future Royalties
NoncashRoyaltyRevenueSaleOfFutureRoyalties
50599000
ptct Noncash Interest Expense Liability Related To Sale Of Future Royalties
NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
155039000
ptct Noncash Interest Expense Liability Related To Sale Of Future Royalties
NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
56031000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
217800000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5700000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-125000000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1486000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-4298000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
2179000
ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
3954000
ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-3107000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1931000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-4594000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1923000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
5484000
ptct Clearpoint Equity Investment Fv Ni Realized Gain Loss
ClearpointEquityInvestmentFvNiRealizedGainLoss
-782000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
-622000
ptct Issuance Of Stock For Milestone Payment
IssuanceOfStockForMilestonePayment
29570000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-76000
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
-135000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-50909000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
9947000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
89000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
891000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1574000
us-gaap Share Based Compensation
ShareBasedCompensation
57376000
us-gaap Share Based Compensation
ShareBasedCompensation
85128000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
147000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-3394000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4922000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14121000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107957000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-59467000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
39029000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
9887000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-7909000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-4597000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-417000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
40434000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4733000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1756000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-801000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-127000
ptct Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
-1800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77684000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58130000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2735000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22872000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
28056000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
476680000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
49614000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26378000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
290836000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
21544000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
41624000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12078000
ptct Proceeds From Sale And Maturity Of Clearpoint Equity Investment
ProceedsFromSaleAndMaturityOfClearpointEquityInvestment
2594000
ptct Proceeds From Principal Payment Of Clearpoint Convertible Debt Security
ProceedsFromPrincipalPaymentOfClearpointConvertibleDebtSecurity
10000000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
65017000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
69285000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-223530000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-82319000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5320000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
23771000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1973000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3805000
ptct Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
241792000
ptct Payments On Deferred Consideration Obligation
PaymentsOnDeferredConsiderationObligation
18200000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
282000
ptct Payment Of Finance Lease Principal
PaymentOfFinanceLeasePrincipal
1490000
ptct Payment Of Finance Lease Principal
PaymentOfFinanceLeasePrincipal
1379000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
229395000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25915000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1325000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70494000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-114515000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
610284000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295925000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
539790000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181410000
us-gaap Interest Paid Net
InterestPaidNet
5823000
us-gaap Interest Paid Net
InterestPaidNet
34020000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12781000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
13631000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2204000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
470000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5786000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
2346000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
44963000
ptct Noncash Or Part Noncash Fixed Assets Tenant Improvement Allowance
NoncashOrPartNoncashFixedAssetsTenantImprovementAllowance
18675000
CY2024Q3 ptct Milestone Payable
MilestonePayable
50000000
CY2023Q3 ptct Milestone Payable
MilestonePayable
2500000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.        The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. The Company’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. The Company’s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. The Company’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. The Company believes that this allows it to maximize value for all its stakeholders. The Company has a diversified therapeutic portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life-threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged two years and older. Translarna also has marketing authorization in Russia for the treatment of nmDMD in patients aged two years and older and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory, as well as in various other countries. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission (“EC”) following reassessment by the European Medicines Agency (“EMA”) of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, the Company also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use (“CHMP”), gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. In January 2024, the CHMP issued a negative opinion for the renewal of the conditional marketing authorization following a re-examination procedure. In May 2024, the EC decided not to adopt the CHMP’s negative opinion for the renewal of the conditional marketing authorization of Translarna and returned such opinion to the CHMP for re-evaluation. In June 2024, following the EC’s request for re-review, the CHMP issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. On October 18, 2024, the CHMP maintained its negative opinion for the renewal of the conditional marketing authorization following the requested reexamination procedure. In accordance with EMA regulations, the opinion will be reviewed by the EC which is expected to decide on opinion adoption approximately 67 days from the date of issuance. If the EC adopts the negative opinion, Translarna would no longer have marketing authorization in the member states of the EEA. The marketing authorization for Translarna remains in effect, pending the EC’s potential adoption of the negative opinion. Based on the timeline of these procedures, the Company expects the marketing authorization for Translarna to remain in effect approximately through the end of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Translarna is an investigational new drug in the United States. Following the Company’s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (“FDA”) to gain clarity on the regulatory pathway for a potential re-submission of a New Drug Application (“NDA”) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA re-submission. The Company held a Type C meeting with the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">FDA in the fourth quarter of 2023 to discuss the totality of Translarna data. <span style="background:#ffffff;">Based on feedback from the FDA, the Company re-submitted the NDA in July 2024, based on the results from Study 041 and from the Company’s international drug registry study for nmDMD patients receiving Translarna. In October 2024, the FDA accepted for review the resubmission of the NDA for Translarna for the treatment of nmDMD. As this was an NDA resubmission following a complete response letter to the NDA which was filed over protest in 2016, the FDA is not obligated to follow the review timelines under Prescription Drug User Fee Act guidelines and an action date has not been provided.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has developed Upstaza™ (eladocagene exuparvovec), a gene therapy used for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare central nervous system (“CNS”) disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. In March 2024, the Company submitted a biologics license application (“BLA”) for eladocagene exuparvovec for the treatment of AADC deficiency in the United States. In May 2024, the FDA accepted for filing the BLA and granted priority review with a target regulatory action date of November 13, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company holds the rights for the commercialization of Tegsedi® (inotersen) and Waylivra® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy (“FPL”). Waylivra has also received marketing authorization in the EU for the treatment of FCS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi has also received marketing authorization for the treatment of SMA in over 100 countries. In May <span style="letter-spacing:-0.1pt;">2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the Company’s most advanced clinical stage molecules is sepiapterin. Sepiapterin is a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. In May 2023, the Company announced that the primary endpoint was achieved in its registration-directed Phase 3 trial for sepiapterin for phenylketonuria (“PKU”). The primary endpoint of the study was the achievement of statistically-significant reduction in blood Phe level. In March 2024, the Company submitted a marketing authorization application (“MAA”) to the EMA for sepiapterin for the treatment of PKU in the EEA, which was validated and accepted for review by the EMA in May 2024. In the third quarter of 2023, the Company participated in a pre-NDA meeting with the FDA. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA requested that PTC complete a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. In July 2024<span style="background:#ffffff;">, following completion of the in-life portion of the study, </span>the Company submitted an NDA to the FDA for sepiapterin for the treatment of PKU in the United States. In September 2024, the FDA accepted for filing the NDA, with a target regulatory action date of July 29, 2025. PTC also made a regulatory submission for sepiapterin for the treatment of PKU in Brazil in the third quarter of 2024, and expects to do the same in Japan in the fourth quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, the Company announced interim data from the 12-week placebo-controlled phase. In June 2024, the Company announced additional interim results from the Phase 2 study of PTC518. At month 12, PTC518 treatment demonstrated durable dose-dependent lowering of mutant HTT (“mHTT”) protein in the blood and dose-dependent lowering of mHTT protein in the cerebrospinal fluid in the interim cohort of stage 2 patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments. Furthermore, following 12 months of treatment, PTC518 continued to be well tolerated. Based on its review of the interim Phase 2 study data, the FDA lifted the partial clinical hold on the program. In September 2024, the FDA granted Fast Track designation to the PTC518 program for the treatment of HD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company’s ferroptosis and inflammation platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s ferroptosis and inflammation platform are vatiquinone and utreloxastat. The Company announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia (“FA”), called MOVE-FA, in May 2023. While the study did not meet its primary endpoint, vatiquinone treatment did demonstrate significant benefit on key disease subscales, including the upright stability subscale, as well as on other disease relevant endpoints. In the first quarter of 2024, the Company met with the FDA, who expressed willingness to review an NDA for vatiquinone for the treatment of Friedreich ataxia based on the MOVE-FA trial as well as data from the ongoing open label extension study following the MOVE-FA trial. In October 2024, the Company announced that the pre-specified endpoint for two different FA long-term extension studies was met, with statistically significant evidence of durable treatment benefit on disease progression. The Company plans to submit an NDA for vatiquinone for the treatment of FA in the United States in December 2024. The Company initiated a Phase 2 registration directed trial of utreloxastat for amyotrophic lateral sclerosis, or ALS, in the first quarter of 2022. The Company expects topline results from this trial in the fourth quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2024, the Company had an accumulated deficit of approximately $3,581.0 million. The Company has financed its operations to date primarily through the private offerings of convertible senior notes (see Note 9), public and “at the market offerings” of common stock, proceeds from royalty purchase agreements (see Note 2), net proceeds from the Company’s borrowings under its credit agreement with Blackstone (see Note 9), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017, and Upstaza for the treatment of AADC deficiency in the EEA since 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, milestone and royalty payments from Roche, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months. </p>
ptct Number Of Products
NumberOfProducts
2
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3581000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
526001000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
594001000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
13789000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
16283000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
539790000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
610284000
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2738000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
952000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
24440000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
17991000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8493000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11634000
CY2024Q3 us-gaap Inventory Net
InventoryNet
35671000
CY2023Q4 us-gaap Inventory Net
InventoryNet
30577000
us-gaap Inventory Write Down
InventoryWriteDown
2500000
us-gaap Inventory Write Down
InventoryWriteDown
400000
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1300000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1200000
CY2024Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
700000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
500000
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
400000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
700000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-46900000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
2200000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
5900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
19500000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
7100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
21500000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
4049000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
5490000
us-gaap Operating Lease Cost
OperatingLeaseCost
15173000
us-gaap Operating Lease Cost
OperatingLeaseCost
16463000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1581000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1376000
us-gaap Variable Lease Cost
VariableLeaseCost
3623000
us-gaap Variable Lease Cost
VariableLeaseCost
4140000
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
308000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
271000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
750000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
866000
CY2024Q3 ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
5938000
CY2023Q3 ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
7137000
ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
19546000
ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
21469000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y18D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y6M18D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0806
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0869
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M3D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P9Y3D
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0780
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0780
us-gaap Operating Lease Payments
OperatingLeasePayments
12963000
us-gaap Operating Lease Payments
OperatingLeasePayments
11479000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1490000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1379000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1510000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
1621000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5786000
ptct Right Of Use Asset Decrease Due To Lease Modifications And Terminations Obtained In Exchange For Finance Lease Liability
RightOfUseAssetDecreaseDueToLeaseModificationsAndTerminationsObtainedInExchangeForFinanceLeaseLiability
31763000
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-33908000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3929000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16235000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3000000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16205000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
3000000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13973000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
3000000
CY2024Q3 ptct Lessee Operating Lease Liability To Be Paid Year Four And After
LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter
139266000
CY2024Q3 ptct Finance Lease Liability To Be Paid Year Four And After
FinanceLeaseLiabilityToBePaidYearFourAndAfter
15000000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
189608000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
24000000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
92725000
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
5784000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
96883000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
18216000
CY2024Q2 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
32333000
CY2024Q3 ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss
6018000
CY2024Q3 ptct Marketable Equity Investments And Convertible Debt Securities Realized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesRealizedGainLoss
-622000
CY2024Q3 ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss Foreign Currency Transaction
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction
400000
CY2024Q3 ptct Marketable Equity Investments And Convertible Debt Securities Purchases
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases
32208000
CY2024Q3 ptct Proceeds From Sale And Redemption Of Marketable Equity Investments And Convertible Debt Securities
ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities
31051000
CY2024Q3 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
39286000
CY2023Q2 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
148115000
CY2023Q3 ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss
-3931000
CY2023Q3 ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss Foreign Currency Transaction
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction
-1426000
CY2023Q3 ptct Marketable Equity Investments And Convertible Debt Securities Purchases
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases
8219000
CY2023Q3 ptct Proceeds From Sale And Redemption Of Marketable Equity Investments And Convertible Debt Securities
ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities
7830000
CY2023Q3 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
143147000
CY2023Q4 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
41261000
ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss
3946000
ptct Marketable Equity Investments And Convertible Debt Securities Realized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesRealizedGainLoss
-622000
ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss Foreign Currency Transaction
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction
-3289000
ptct Marketable Equity Investments And Convertible Debt Securities Purchases
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases
49614000
ptct Proceeds From Sale And Redemption Of Marketable Equity Investments And Convertible Debt Securities
ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities
51624000
CY2024Q3 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
39286000
CY2022Q4 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
134457000
ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLoss
-2217000
ptct Marketable Equity Investments And Convertible Debt Securities Realized Gain Loss
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesRealizedGainLoss
-782000
ptct Marketable Equity Investments And Convertible Debt Securities Unrealized Gain Loss Foreign Currency Transaction
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesUnrealizedGainLossForeignCurrencyTransaction
-17000
ptct Marketable Equity Investments And Convertible Debt Securities Purchases
MarketableEquityInvestmentsAndConvertibleDebtSecuritiesPurchases
26378000
ptct Proceeds From Sale And Redemption Of Marketable Equity Investments And Convertible Debt Securities
ProceedsFromSaleAndRedemptionOfMarketableEquityInvestmentsAndConvertibleDebtSecurities
14672000
CY2023Q3 ptct Equity Investments And Convertible Debt Securities
EquityInvestmentsAndConvertibleDebtSecurities
143147000
CY2024Q3 ptct Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount
0
CY2023Q4 ptct Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount
0
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
455568000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2538000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
8000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
458098000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
259778000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
340000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
260104000
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2024Q3 us-gaap Debt Securities Trading Realized Gain Loss
DebtSecuritiesTradingRealizedGainLoss
800000
us-gaap Debt Securities Trading Realized Gain Loss
DebtSecuritiesTradingRealizedGainLoss
800000
CY2023Q3 us-gaap Debt Securities Trading Realized Gain Loss
DebtSecuritiesTradingRealizedGainLoss
0
us-gaap Debt Securities Trading Realized Gain Loss
DebtSecuritiesTradingRealizedGainLoss
-300000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
8000
CY2024Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
14984000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
8000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
14984000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
12000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
44446000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
1648000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
14000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
46094000
CY2024Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
458098000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
260104000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
46209000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
62643000
CY2024Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
6012000
CY2024Q3 ptct Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
23032000
CY2023Q4 ptct Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
27500000
CY2024Q3 ptct Sales Allowance And Other Related Costs
SalesAllowanceAndOtherRelatedCosts
65782000
CY2023Q4 ptct Sales Allowance And Other Related Costs
SalesAllowanceAndOtherRelatedCosts
77176000
CY2024Q3 ptct Sales Rebates Current
SalesRebatesCurrent
102919000
CY2023Q4 ptct Sales Rebates Current
SalesRebatesCurrent
131334000
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
14016000
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
74111000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13292000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6045000
CY2024Q3 ptct Milestone Payable
MilestonePayable
50000000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15084000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13174000
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
336346000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
391983000
CY2024Q3 ptct Accrued Restructuring Costs
AccruedRestructuringCosts
300000
CY2023Q4 ptct Accrued Restructuring Costs
AccruedRestructuringCosts
9000000.0
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-106654000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-132970000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-297409000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-470812000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76925523
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76925523
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75377997
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75377997
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76716340
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74618611
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.76
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.31
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12769789
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14850885
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19755000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26942000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
57376000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
85128000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
117800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2023Q4 ptct Liability Sale Of Future Royalties
LiabilitySaleOfFutureRoyalties
1814097000
ptct Liability Sale Of Future Royalties Royalty Revenue Payable
LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable
128877000
ptct Liability Sale Of Future Royalties Interest Expense
LiabilitySaleOfFutureRoyaltiesInterestExpense
155039000
ptct Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
241792000
CY2024Q3 ptct Liability Sale Of Future Royalties
LiabilitySaleOfFutureRoyalties
2082051000
CY2024Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.099
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
800000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
3043000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
12160000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
12160000
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
12160000
CY2024Q3 ptct Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter
55079000
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
94602000
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
330368000
us-gaap Indefinite Lived Intangible Assets Period Increase Decrease
IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
0
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2024Q3 us-gaap Goodwill
Goodwill
82300000
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001070081-24-000023-index-headers.html Edgar Link pending
0001070081-24-000023-index.html Edgar Link pending
0001070081-24-000023.txt Edgar Link pending
0001070081-24-000023-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20240930.xsd Edgar Link pending
tmb-20240930x10q.htm Edgar Link pending
tmb-20240930xex31d1.htm Edgar Link pending
tmb-20240930xex31d2.htm Edgar Link pending
tmb-20240930xex32d1.htm Edgar Link pending
tmb-20240930xex32d2.htm Edgar Link pending
tmb-20240930_def.xml Edgar Link unprocessable
tmb-20240930_lab.xml Edgar Link unprocessable
tmb-20240930_pre.xml Edgar Link unprocessable
tmb-20240930x10q_htm.xml Edgar Link completed
tmb-20240930_cal.xml Edgar Link unprocessable